Table 5 Data after 1 year of follow-up treatment
Total | 24-HUPRO(g/L) | ALB(g/L) | SCr (μmol/L) | BUN (mmol/L) | New DM(%) |
|---|---|---|---|---|---|
FSGS-(N = 146) | 1.27 ± 1.58 | 36.82 ± 5.75 | 63.89 ± 17.05 | 1.49 ± 2.20 | 22/146 (15.1) |
FSGS(N = 34) | 2.18 ± 2.34* | 34.74 ± 8.86 | 76.99 ± 35.05* | 2.74 ± 2.71 | 4/34 (11.8) |
Pred + Ctx | |||||
FSGS-(N = 81) | 1.37 ± 1.83 | 36.22 ± 5.94 | 59.36 ± 13.46 | 5.30 ± 1.59 | 11/81 (13.6) |
FSGS(N = 18) | 1.44 ± 1.95 | 35.16 ± 8.77 | 72.55 ± 43.73 | 7.33 ± 2.88** | 2/18 (11.1) |
Ped + CsA | |||||
FSGS-(N = 34) | 1.11 ± 1.24 | 37.68 ± 5.90 | 72.50 ± 21.68 | 6.17 ± 1.60 | 5/34 (14.7) |
FSGS+(N = 9) | 2.89 ± 2.81* | 34.28 ± 7.59 | 77.74 ± 12.67 | 7.25 ± 3.14 | 2/9 (11.1) |
Ped + TAC | |||||
FSGS-(N = 31) | 1.15 ± 1.11 | 37.46 ± 4.93 | 67.08 ± 16.16 | 6.21 ± 1.80 | 6/31 (19.4) |
FSGS+ (N = 7) | 2.71 ± 2.49* | 35.07 ± 11.80 | 87.00 ± 31.15* | 6.49 ± 1.69 | 0 |